PubRank

Jennifer J Knox

Author PubWeight™ 63.86‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009 8.16
2 Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010 4.71
3 Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 2013 3.70
4 Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol 2012 3.56
5 Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol 2012 2.84
6 Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 2009 2.78
7 The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 2010 2.73
8 Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study. Eur J Cancer 2012 2.54
9 Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008 2.40
10 Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010 2.10
11 Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology 2010 1.68
12 An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. Eur J Cancer 2011 1.60
13 Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer 2010 1.52
14 Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. J Clin Endocrinol Metab 2008 1.37
15 Supporting treatment decision making in advanced cancer: a randomized trial of a decision aid for patients with advanced colorectal cancer considering chemotherapy. J Clin Oncol 2011 1.29
16 Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases. Am J Clin Oncol 2006 1.29
17 Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer 2007 1.27
18 Sorafenib for metastatic renal cancer: the Princess Margaret experience. Am J Clin Oncol 2008 1.22
19 Sunitinib in solid tumors. Expert Opin Investig Drugs 2009 1.20
20 Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer 2012 1.12
21 Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer 2013 1.12
22 Conformal radiotherapy in the adjuvant treatment of gastric cancer: Review of 82 cases. Int J Radiat Oncol Biol Phys 2006 1.00
23 Impact and feasibility of a comprehensive geriatric assessment in the oncology setting: a pilot study. Am J Clin Oncol 2012 0.98
24 Endoscopic or percutaneous biliary drainage for Klatskin tumors? J Vasc Interv Radiol 2012 0.97
25 The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Target Oncol 2013 0.95
26 A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma. Cancer 2015 0.92
27 Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program. Oncology 2010 0.91
28 Health-related quality of life in esophageal cancer: effect of neoadjuvant chemoradiotherapy followed by surgical intervention. J Thorac Cardiovasc Surg 2009 0.88
29 Renal cell carcinoma bone metastases: clinical advances. Ther Adv Med Oncol 2010 0.87
30 The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy. Cancer 2011 0.86
31 State-of-the-art in the management of locally advanced and metastatic gallbladder cancer. Curr Opin Oncol 2013 0.86
32 Sequence dependence of MEK inhibitor AZD6244 combined with gemcitabine for the treatment of biliary cancer. Clin Cancer Res 2012 0.83
33 Adjuvant therapy for intrahepatic cholangiocarcinoma: the debate continues. Oncologist 2012 0.82
34 Sorafenib and radiation therapy for the treatment of advanced hepatocellular carcinoma. J Gastrointest Cancer 2012 0.81
35 A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium. J Thorac Oncol 2009 0.80
36 Cancer of the gallbladder and extrahepatic bile ducts. Curr Probl Surg 2007 0.80
37 Structured electronic operative reporting: comparison with dictation in kidney cancer surgery. Int J Med Inform 2012 0.79
38 Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers. BJU Int 2012 0.79
39 Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium. Clin Genitourin Cancer 2013 0.79
40 Outcome of adjuvant therapy in biliary tract cancers. Am J Clin Oncol 2015 0.77
41 Response to letter 'outcome of second-line chemotherapy for biliary tract cancer'. Eur J Cancer 2012 0.75
42 Canadian kidney cancer forum 2008. Can Urol Assoc J 2008 0.75
43 Use of a clinical assistant to screen patients with genitourinary cancer to encourage entry into clinical trials and use of supportive medication: a pilot project at a Canadian cancer center. Clin Genitourin Cancer 2013 0.75
44 The comprehensive geriatric assessment in oncology: promises, pitfalls, and practicalities. Hosp Pract (1995) 2010 0.75
45 Retreatment of men with metastatic castrate-resistant prostate cancer with abiraterone. Prostate 2014 0.75
46 Effects of Statin, Aspirin or Metformin Use on Recurrence-Free and Overall Survival in Patients with Biliary Tract Cancer. Hepatogastroenterology 2015 0.75
47 When your best is not good enough. J Cancer Educ 2011 0.75